Experts take a broad look at how molecular profiling has impacted the treatment landscape of non–small cell lung cancer.
Back
Major Advances in NSCLC: EGFR Exon 20 Insertion Mutations
Practical perspectives on recent data and FDA approvals supporting novel agents that target EGFR exon 20 insertion mutations in non–small cell lung cancer.
Major Advances in NSCLC: EGFR Exon 20 Insertion Mutations
Episodes
All
All
Erminia Massarelli, MD, MS, PhD, shares insight on potential barriers to appropriate molecular testing in patients with non–small cell lung cancer.
In the setting of non–small cell lung cancer, experts consider the importance of EGFR exon 20 insertion mutations as a therapeutic target.
Current standard-of-care approaches toward the management of patients with non–small cell lung cancer with EGFR exon 20 insertion mutations.
Considerations for the FDA approval and practical use of amivantamab in patients with EGFR exon 20 insertion mutations in non-small cell lung cancer.
Considerations for the FDA approval and practical use of mobocertinib in patients with EGFR exon 20 insertion mutations in NSCLC.
Shared insight on the differences between amivantamab and mobocertinib and when they may be appropriately used in patients with NSCLC.
Experts briefly review a number of other agents in NSCLC that target EGFR exon 20 insertion mutations.
Before closing out their discussion on EGFR exon 20 insertion mutations in NSCLC, experts share their thoughts on the future treatment landscape and potential unmet needs.
Advertisement
Advertisement
Trending on OncLive
1
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
2
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
3
Etentamig Meets PFS, ORR Primary End Points in Triple-Class Exposed R/R Myeloma
4
FDA Grants Breakthrough Therapy Designation to JBS-003 for Radiation De-Escalation in HPV+ Oropharyngeal Cancer
5